Trimethylamine N-oxide: a meta-organismal axis linking the gut and fibrosis.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic pathways and existing literature without new human data or systematic review methodology.
PubMed 39180015 · doi:10.1186/s10020-024-00895-8
What was done
This narrative review synthesized literature on the meta-organismal metabolic pathway of trimethylamine N-oxide (TMAO)—in which gut microbiota metabolize dietary choline, phosphatidylcholine, and L-carnitine into trimethylamine (TMA), followed by hepatic oxidation via flavin-containing monooxygenase 3 (FMO3)—and evaluated its association with pathologic tissue fibrosis across organ systems.
What was found
The abstract reports no quantitative values or statistical effect sizes. It qualitatively describes that chronic exposure to elevated TMAO is associated with vascular injury and an increased propensity for fibrosis in chronic kidney disease, heart failure, metabolic dysfunction-associated steatotic liver disease, and systemic sclerosis.
Why it matters
Tissue fibrosis is a central driver of end-stage organ dysfunction with limited effective therapies. Elucidating the gut-microbiota-dependent TMAO axis highlights a potential modifiable target through dietary or microbiome-directed interventions.
Limits
The abstract describes a narrative review without systematic search criteria, quality appraisal, or study counts (n is not reported). It provides no primary quantitative data, effect estimates, or clinical trial evidence, and mechanistic or correlational associations cannot establish causality in human disease.
Cited by
- supports Dietary compounds including choline and carnitine are converted by gut microbes into TMA, which is then metabolized by the host liver into TMAO.